secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2026-05-21T20:30:35+00:00
Accession:  0001437749-26-018106
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica shareholders re-elect all seven directors, approve auditor, exec compensation, and share increase
--------------------------------------------------------------------------------

- All seven incumbent directors re-elected; Daniel O'Connor received 5,130,879 votes withheld vs. ~200,000 for others.
- Baker Tilly US, LLP ratified as auditor for FY 2026 with 20,950,404 votes for and 578,926 against.
- Advisory vote on executive compensation approved: 9,928,381 for, 271,093 against, 149,163 abstain.
- Amendment to 2019 Omnibus Incentive Plan to increase shares by 3.5M approved: 9,693,413 for, 510,487 against.
- All proposals passed with broker non-votes of 11,180,693 on director election and other non-routine items.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774926018106/0001437749-26-018106-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774926018106/dmtp20260520_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-018106

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer